Literature DB >> 7725763

[Re-treatment with interferon-alpha in chronic hepatitis B and C virus infection].

G Teuber1, H P Dienes, K H Meyer zum Büschenfelde, G Gerken.   

Abstract

The efficacy of interferon-alpha retreatment was assessed in patients with chronic hepatitis B or C, not responding to a first cycle of interferon or reactivating thereafter. 27 patients with chronic hepatitis B and 25 patients with chronic hepatitis C were investigated. After an interval of at least 6 months these patients received an interferon-alpha retreatment in a higher dosage schedule and with a different interferon-alpha subtype. In patients with chronic hepatitis B a loss of serum HBV-DNA was observed in 59% patients after interferon-alpha retreatment. HBeAg seroconversion occurred in 8 of these patients. In chronic hepatitis C 32% of the patients responded completely to the second cycle of interferon-alpha treatment with a normalization of ALT associated with a loss of serum HCV-RNA. A partial response with a marked reduction of ALT was seen in 4 patients. In chronic hepatitis B and C a complete or partial response to the retreatment was closely associated with the response status after the first cycle. Thus, interferon retreatment seems to be effective in patients with chronic hepatitis B or C, especially in the subgroup of patients exhibiting a partial or complete response after the first interferon treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7725763

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  2 in total

1.  Safety and efficacy of interferon retreatment in children with chronic hepatitis B.

Authors:  A Ballauff; T Schneider; P Gerner; P Habermehl; R Behrens; S Wirth
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

Review 2.  Future prospectives for the management of chronic hepatitis B.

Authors:  W F Leemans; H L A Janssen; R A de Man
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.